Changku Jia

Dr. Changku Jia


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2020 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
HZHanzhang Zhu
Hanzhang Zhu
YSYuqiang Shan
Yuqiang Shan
KGKe Ge
Ke Ge
JLJun Lu
Jun Lu
WKWencheng Kong
Wencheng Kong
CJChangku Jia
Changku Jia

Verified
Journal Article
Open access
PDF file
HZHanzhang Zhu
Hanzhang Zhu
WZWeijiang Zhou
Weijiang Zhou
YWYafeng Wan
Yafeng Wan
JLJun Lu
Jun Lu
KGKe Ge
Ke Ge
CJChangku Jia
Changku Jia
Pancreatic cancer is one of the most lethal malignant tumors. However, the molecular mechanisms responsible for its progression are little known. This study aimed to understand the regulatory role of CD44V3 in pancreatic cancer. A Kaplan–Meier analysis was performed to reveal the correlation between CD44/CD44V3 expression and the prognosis of pancreatic cancer patients. CD44V3 and U2AF1 were knocked down using shRNAs. The proliferation, migration, invasion, and stemness of two pancreatic cell lines, BxPC-3 and AsPC-1, were examined. The expression of CD44V3, cancer-associated markers, and the activation of AKT signaling were detected by qRT-PCR and Western blot. Both CD44 and CD44V3 expression levels were associated with a poor prognosis in pancreatic cancer patients. Interestingly, the expression of CD44V3, instead of CD44, was greatly increased in tumor tissues. CD44V3 knockdown inhibited the proliferation, migration, invasion, and stemness of cancer cells. CD44V3 splicing was regulated by U2AF1 and downregulation of U2AF1 enhanced CD44V3 expression, which promoted pancreatic cancer progression. CD44V3 is an important cancer-promoting factor, which may serve as a potential candidate for pancreatic cancer intervention.

18 January 2021 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
HZHanzhang Zhu
Hanzhang Zhu
YSYuqiang Shan
Yuqiang Shan
KGKe Ge
Ke Ge
JLJun Lu
Jun Lu
WKWencheng Kong
Wencheng Kong
CJChangku Jia
Changku Jia
This study aimed to analyze the relative expression of Eukaryotic Translation Initiation Factor 3 Subunit B (EIF3B) in pancreatic cancer and elucidate its contribution to this disease.Relative expr...

1 January 2023 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
LZLiang Zhang
Liang Zhang
JHJiawei Hong
Jiawei Hong
WCWei Chen
Wei Chen
WZWei Zhang
Wei Zhang
XLXi Liu
Xi Liu
SZShusen Zheng
Shusen Zheng
The progression of hepatocellular carcinoma (HCC) remains a huge clinical challenge, and elucidation of the underlying molecular mechanisms is critical to develop effective therapeutic strategy. Dumbbell former 4 (DBF4) complexes with cell division cycle 7 (CDC7) to form DBF4-dependent kinase (DDK), playing instrumental roles in tumor cell survival, whereas its roles in HCC remain elusive. This study revealed that DBF4 expression was upregulated in HCC and constituted an independent prognostic factor of patient survival. We identified p65 as an upstream inducer which increased DBF4 expression by directly binding to its promoter. DBF4 accelerated HCC cell proliferation and tumorigenesis in vitro and in vivo. Mechanistically, DBF4 complexed with CDC7 to bind to the coiled coil domain of STAT3 and activate STAT3 signaling through XPO1-mediated nuclear exportation. Notably, p65 enhanced the nuclear transport of DDK and DDK-STAT3 interaction by transcriptionally upregulating XPO1. DBF4 expression positively correlated with activated STAT3 and XPO1 in HCC tissues. Furthermore, combining DDK inhibitor XL413 with anti-PD-1 immunotherapy dramatically suppressed HCC growth and prolonged the survival of HCC-bearing mouse. Our findings reveal that DDK activates STAT3 pathway and facilitates HCC progression, and demonstrate the proof of the concept of targeting DDK to improve the efficacy of HCC immunotherapy.

7 March 2022 in BioFactors
Verified
Journal Article
Closed access
HZHanzhang Zhu
Hanzhang Zhu
WZWeijiang Zhou
Weijiang Zhou
YWYafeng Wan
Yafeng Wan
JLJun Lu
Jun Lu
KGKe Ge
Ke Ge
CJChangku Jia
Changku Jia

3 May 2022 in Future Oncology
Verified
Journal Article
Closed access
ZYZhentao Yang
Zhentao Yang
WCWei Chen
Wei Chen
HZHai Zhu
Hai Zhu
LZLiang Zhang
Liang Zhang
KZKe Zhou
Ke Zhou
CJChangku Jia
Changku Jia
Objective: To investigate the prognostic value of DNA methylation of tumor suppressor genes for hepatocellular carcinoma (HCC) recurrence after liver transplantation. Methods: APC gene was selected...